-
Novel Liver Ring Trial Set to Revolutionize Drug Safety Assessment
In a first-of-its-kind initiative, TissUse (a leader in organ-on-chip technology) announced the commencement of the Liver Ring Trial. This collaborative effort involving ESQLabs (a computational model expert), UCB, a global biopharmaceutical company and initiator of the ring trial, and five other pharmaceutical companies (Orion Corporation, Sanofi-Aventis Recherche & Développement, Technologie Servier/Biologie Servier1, AstraZeneca, and Boehringer Ingelheim) aims to validate the reproducibility and accuracy of a Liver Micro-Physiological System (MPS) in predicting drug-induced liver injury (DILI) and intrinsic clearance, marking a paradigm shift in non-clinical drug assessment. Innovating with Microfluidic Organ-on-Chips The Liver Ring Trial leverages TissUse’s cutting-edge HUMIMIC organ-on-chip technology, which has been central to the development of the Liver…
-
New Multi-Organ-Chip project towards vaccine & drug candidate testing for Tuberculosis
TissUse will receive funding from the Bill & Melinda Gates Foundation to develop a human preclinical lung-liver-lymph node co-culture on a HUMIMIC Chip infectable with Mycobacterium tuberculosis. This collaboration will contribute to the development of Tuberculosis vaccine candidates and treatment. TissUse announced today that it has received funding from the Bill & Melinda Gates Foundation for a 3-year project. The joint research activities have the goal to develop a vascularized microphysiological system interconnecting human lung, liver and lymph node organoids capable of screening Tuberculosis vaccine candidates and treatment modalities. TissUse will receive funding from the Bill & Melinda Gates Foundation to develop a human preclinical lung-liver-lymph node co-culture on a…
-
Philip Morris International and TissUse develop a human aerosol test platform to emulate the entire human respiratory tract
PMI and TissUse have signed a collaboration agreement to utilize PMI’s InHALES technology in combination with TissUse’s proprietary Multi-Organ-Chip (MOC) platform to enable inhalation exposure of functional human tissues in homeostasis at minute scale in vitro. The two partners will develop a highly innovative integrated human aerosol test platform that emulates the entire human respiratory tract with regard to dimension and architecture. PMI has established a platform that perfectly matches the architecture and characteristics of the human respiratory tract (InHALES). TissUse has established the widely used HUMIMIC Multi-Organ-Chip (MOC) platform, which enables functional human tissue response in vitro. A plug&play interface between the two technologies will allow physiologically relevant exposure…
-
TissUse GmbH appoints Dr. Reyk Horland as new CEO while TissUse’s founder
On its 10th company anniversary, TissUse GmbH appoints Dr. Reyk Horland, previously VP Business Development, as the new CEO. Reyk Horland has been with TissUse since it was founded in 2010 and has implemented a profitable product business with a remarkable annual sales growth rate since the market launch of the HUMIMIC® technology in 2014. His business network includes leading pharmaceutical and consumer product companies as well as regulatory authorities and outstanding research institutions worldwide. "I look forward to achieving exceptional business expansion with proprietary products for meaningful drug evaluation and personalized precision medicine. With its strategic positioning, TissUse will also be able to benefit from the dynamic changes in…
